Natco Pharma Limited will host an investor meet on August 19, 2026, in Mumbai. The event is scheduled from 5:00 pm onwards and is being organized by Nuvama Wealth Management Limited and ICICI Securities Limited. Company officials will participate in the group meeting to engage with investors.

The interaction is structured as an in-person group meet. The schedule is subject to change due to exigencies on the part of the investor or the company. The management has confirmed that no unpublished price-sensitive information (UPSI) pertaining to the company will be discussed during the interactions.

Meeting Details

The disclosure was made pursuant to Regulation 30(6) read with Para A of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ch. Venkat Ramesh, Company Secretary and Compliance Officer, signed the intimation on August 16, 2026.

Natco Pharma declared an interim dividend of ₹1.50 per equity share for the financial year 2026-27. The company's board of directors also approved a fund raising initiative of up to ₹20 billion.

Corporate Actions

The dividend payout reflects the company's commitment to returning value to shareholders. Simultaneously, the approval for raising funds indicates strategic planning for capital allocation or debt management.

Key Decisions

• Interim dividend: ₹1.50 per share
• Fund raising approval: Up to ₹20 billion

These actions were confirmed during the recent board meeting.

Dividend Details

The Board of Directors, in its meeting held on August 14, 2026, declared the interim dividend at a rate of 75% on the face value of ₹2 per share. Shareholders whose names appear on the register as of the record date will be eligible for the payment.

The payment of the interim dividend will begin from August 26, 2026.